Novartis meningitis vaccine used at 2nd US campus

(AP)—Swiss drug maker Novartis says a second U.S. university is using its new vaccine against meningitis B.

Novartis said Monday that the , Bexsero, is being used at the University of California Santa Barbara until March 7 to help protect 20,000 students and staff after an .

The vaccine shot for the B strain of the meningitis bacteria is approved for use in Europe, Australia and Canada, but not yet for general use in the United States.

But the U.S. Food and Drug Administration has now approved the use of Bexsero twice in response to outbreaks at U.S. college campuses. It is the first vaccine against the B strain of meningitis.

Princeton University says almost 5,300 people got the vaccine last year in an effort to halt an outbreak there.

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Princeton vaccine reaches 90 percent of eligible

Dec 13, 2013

Princeton University officials say more than 90 percent of the eligible students and staff received a meningitis vaccine this week as part of the university's effort to halt an outbreak.

Recommended for you

Determine patient preferences by means of conjoint analysis

3 hours ago

The Conjoint Analysis (CA) method is in principle suitable to find out which preferences patients have regarding treatment goals. However, to widely use it in health economic evaluations, some (primarily methodological) issues ...

FDA approves hard-to-abuse narcotic painkiller

Jul 25, 2014

(HealthDay)—A new formulation of a powerful narcotic painkiller that discourages potential abusers from snorting or injecting the drug has been approved by the U.S. Food and Drug Administration.

Race affects opioid selection for cancer pain

Jul 25, 2014

(HealthDay)—Racial disparities exist in the type of opioid prescribed for cancer pain, according to a study published online July 21 in the Journal of Clinical Oncology.

FDA approves tough-to-abuse formulation of oxycodone

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe ...

Tough-to-abuse formulation of oxycodone approved

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe pain when other ...

User comments